Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253130, C514S318000
Reexamination Certificate
active
07998948
ABSTRACT:
A method of treating esophageal cancer, containing the step of administering to a patient suffering from esophageal cancer, a compound or a salt thereof, wherein the compound is: N-(2-fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-({2-[(azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[methyl(1-methyl-piperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide, or N-(2,5-difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
REFERENCES:
patent: 6790852 (2004-09-01), Brandt et al.
patent: 7253286 (2007-08-01), Funahashi et al.
patent: 7425564 (2008-09-01), Fujiwara et al.
patent: 7531532 (2009-05-01), Matsushima et al.
patent: 7652022 (2010-01-01), Floersheimer et al.
patent: 7855290 (2010-12-01), Matsushima et al.
patent: 2003/0199691 (2003-10-01), Brandt et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0214874 (2004-10-01), Brandt et al.
patent: 2004/0242603 (2004-12-01), Fujiwara et al.
patent: 2005/0009840 (2005-01-01), Cui et al.
patent: 2005/0009842 (2005-01-01), Zemlicka et al.
patent: 2005/0014753 (2005-01-01), Ding et al.
patent: 2005/0245530 (2005-11-01), Borzilleri et al.
patent: 2005/0277652 (2005-12-01), Matsushima et al.
patent: 2006/0252777 (2006-11-01), Kim et al.
patent: 2008/0214815 (2008-09-01), Nagai et al.
patent: 2008/0300273 (2008-12-01), Christensen et al.
patent: 2008/0318924 (2008-12-01), Matsushima et al.
patent: 2008/0319188 (2008-12-01), Matsushima et al.
patent: 2009/0227556 (2009-09-01), Obaishi
patent: 2010/0075944 (2010-03-01), Matsushima et al.
patent: 2010/0311972 (2010-12-01), Nagai
patent: 1 411 046 (2004-04-01), None
patent: 1 415 987 (2004-05-01), None
patent: 1 473 043 (2004-11-01), None
patent: 1 506 962 (2005-02-01), None
patent: 1 719 762 (2006-11-01), None
patent: 1 719 763 (2006-11-01), None
patent: 1 889 836 (2008-02-01), None
patent: 2 058 302 (2009-05-01), None
patent: 2 119 706 (2009-11-01), None
patent: 2007-153894 (2007-06-01), None
patent: 2007-153894 (2007-06-01), None
patent: WO-02/32872 (2002-04-01), None
patent: WO-02/096361 (2002-12-01), None
patent: WO-03/000660 (2003-01-01), None
patent: WO-03/087026 (2003-10-01), None
patent: WO-03/099771 (2003-12-01), None
patent: WO 2004/030524 (2004-04-01), None
patent: WO-2004/076412 (2004-09-01), None
patent: WO-2004/089286 (2004-10-01), None
patent: WO-2005/004607 (2005-01-01), None
patent: WO-2005-004808 (2005-01-01), None
patent: WO-2005/005378 (2005-01-01), None
patent: WO-2005/005389 (2005-01-01), None
patent: WO-2005/010005 (2005-02-01), None
patent: WO-2005/016920 (2005-02-01), None
patent: WO-2005/030140 (2005-04-01), None
patent: WO-2005/040154 (2005-05-01), None
patent: WO-2005/082854 (2005-09-01), None
patent: WO-2005/082855 (2005-09-01), None
patent: WO 2005/115478 (2005-12-01), None
patent: WO-2005/117867 (2005-12-01), None
patent: WO-2006/004636 (2006-01-01), None
patent: WO-2006/014325 (2006-02-01), None
patent: 2007/023768 (2007-03-01), None
patent: WO 2008/026577 (2008-03-01), None
patent: 2008/102870 (2008-08-01), None
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19, 1997.
English translation of International Preliminary Report on Patentability (IPRP—Chapter I) issued in International Application No. PCT/JP2007/066185 dated Mar. 5, 2009 (6 pages).
Matsushima et al., “Preparation of pyridine and pyrimidine derivatives as inhibitors of hepatocyte growth factor receptor (HGFR)”, Hcaplus 2005:977021, Sep. 9, 2005.
Naran et al., “Inhibition of HGF/MET as therapy for malignancy”, Expert Opinion Ther. Targets, vol. 13, No. 5, pp. 569-581, 2009.
English translation of WO 2008/102870 published Aug. 28, 2008.
To et al., “The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers”, Oncology Reports, 5, pp. 1013-1024 (1998).
Rosen et al., “Scatter Factor and angiogenesis”, Advances in Cancer Research, vol. 67, pp. 257-279 (1995).
Maehara et al., “NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells”, British Journal of Cancer, vol. 84, No. 6, pp. 864-873. (2001).
Matsumoto et al., “NK4 (HGF-antagonist/angiagenesis inhbitor) in cancer biology and therapeutics”, Cancer Sci, vol. 94, pp. 321-327 (2003).
Kolibaba et al., “Protein tyrosine kinases and cancer”, B. B. A., 1333, F217-F248, (Jul. 1997), Portland, OR.
Sheijen et al., “Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease”, Oncogene, 21, 3314-333L(2002), Boston, MA.
Blume-Jensen et al., “Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis”, The EMBO Journal, 10, 4121-4128, (1991), Thousand Oaks, CA and Sweden.
Lev et al., “A specific combination of substrates is involved in signal transduction by the kit-encoded receptor” The EMBO Journal, 10, 647-654, (1991), Isreal.
Wang et al., “The Expression of the Proto-Oncogene C-Kit in the Blast Cells of Acute Myeloblastic Leukemia”, Leukemia, 3, 699-702, (1989), Toronto, Canada and Cambridge, MA.
Kanakura et al., “Expression, Function and Activation of The Proto-oncogen c-kit Product in Human Leukemia Cells”, Leukemia and Lymphoma, 10, 35-41, (1993), Osaka, Japan.
Ikeda et al., “Expression and Functional Role of the Proto-oncogene c-kit in Acute Myeloblastic Leukemia Cells”, Blood, 78, 2962-2968, (1991).
Ikeda et al., “Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor”, Experimental Hematology, 21, 1686-1694, (Aug. 1993), Osaka, Japan.
Furitsu et al., “Identification of Mutations in the Coding Sequence of the Proto-oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of c-kit Product”, J. Clin. Invest., 92, 1736-1744, (1993), Osaka, Japan; Rochester; MN and Adelaide, 'South Australia.
Hibi et al , “Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer”, Oncogene, 6, 2291-2296, (1991), Nagoya, Japan.
Sekido et al., “Preferential Expression of c-kit Protooncogene Transcripts in Small Cell Lung Cancer”, Cancer Research, 51, 2416-2419, (May 1, 1991), Nagoya, Japan.
Lasota et al., “Mutations in Exons 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors”, American Journal of Pathology, 157, 1091-1095, (Oct. 2000), Washington, D.C.; Helsinki, Finland and Krakow, Poland.
Taniguchi et al., Effect of c-kit Mutation on Prognosis of Gastrointestinal Stomal Tumors, Cancer Research, 59, 4297-4300, (Sep. 1, 1999), Japan.
Strohmeyer et al., “Expression of the hst-1 and c-kit Protooncogenes in Human Testicular Germ Cell Tumors”, Cancer Research, 51, 1811-1816, (Apr. 1, 1991), CA and Germany.
Tian et al., “Activating c-kit Gene Mutations in Human Germ Cell Tumors”, American Journal of Pathology, 154, 1643-1647, (Jun. 1999), VA.
Tonary et al., “Lack of Expression of c-Kit in Ovarian Cancers Is Associated With Poor Prognosis”, Int. J. Cancer (Pred. Oncol.), 89, 242-250, (2000), Ottawa, Canada.
Natali et al., “Breat Cancer Is Associated With Loss of the c-kit lkit Oncogene Product”. Int. J. Cancer, 52, 713-717, (1992
Nakagawa Takayuki
Obaishi Hiroshi
Birch & Stewart Kolasch & Birch, LLP
EISAI R&D Management Co., Ltd.
Spivack Phyllis G.
LandOfFree
Pharmaceutical composition for treating esophageal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for treating esophageal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treating esophageal cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740321